 |
Panorama of Celltrion headquarters. (Photo=Celltrion) |
[Alpha Biz= Reporter Paul Lee] On the 7th, Celltrion announced that its autoimmune disease treatment, Remsima® SC, achieved a market share of 39% in Germany last year, showing growth of over tenfold in market share in four years.
According to pharmaceutical market research firm IQVIA, Remsima® SC, the world's only infliximab subcutaneous injection (SC) formulation developed by Celltrion, recorded a market share of 39% in Germany as of the fourth quarter of last year.
Celltrion is also expanding its presence in the oncology market in Germany. The company recently signed a contract with a distributor holding approximately 15% market share in the German Bevacizumab market to supply 'Bevacizumab' exclusively. Despite being a late entrant, Celltrion achieved a market share of 24% in the fourth quarter of last year, ranking second in prescriptions among eight Bevacizumab products, including the original.
Celltrion's breast and stomach cancer treatment, 'Herzuma' (Trastuzumab), also recorded a market share of 38% in Germany as of the fourth quarter of last year, surpassing the original and securing the top spot in Trastuzumab prescriptions.
Alphabiz Reporter Kim SangJin(hoondork1977@alphabiz.co.kr)
